Table 2.
Drugs targeting NLRP3 inflammasome mediated pyroptosis in arthritis.
| Categories | Drug names | Related arthritis | Ref |
|---|---|---|---|
| NLRP3 inflammasome direct inhibitors | |||
| NLRP3 direct inhibitors | ICA | OA | (52) |
| CY-09 | OA | (53) | |
| MCC950 | OA | (33) | |
| Leojaponin | GA | (66) | |
| Caspase direct inhibitors | Ac-YVAD-cmk | OA | (29) |
| NSC697923 | GA | (45) | |
| NLRP3 inflammasome indirect inhibitors | |||
| NF- κB inhibitors | |||
| Punicalagin | RA | (41) | |
| Morroniside | OA | (32) | |
| loganin | OA | (51) | |
| Dietary fatty acid | OA | (36) | |
| Lico A | OA | (35) | |
| BF-2 | GA | (69) | |
| ROS or mitochondrial function inhibitors | |||
| MDP | RA | (42) | |
| CF101 | OA | (31) | |
| Gallic Acid | GA | (50) | |
| Corilagin | GA | (40) | |
| Resveratrol | GA | (65) | |
| ASIC1a inhibitors | |||
| amiloride | RA | (39) | |
| PcTx1 | RA | (57) | |
| P2Y14 receptor inhibitors | |||
| HQL6 | GA | (67) | |
| 3-amide-5-aryl benzoic acids | GA | (68) | |
| GSDMD inhibitors | |||
| NSA | GA | (63) | |
| PKA activators | |||
| Wedelolactone | GA | (62) | |
| AMPK activators | |||
| SDF-1 | OA | (55) | |
| Traditional Chinese medicine | |||
| HQH | RA | (56) | |
| BHGZD | RA | (70) | |
| JWJG capsule | RA | (60) | |
ICA, Icariin; NSA, necrosulfonamide; BF-2, Baeckein E; MDP, monomeric derivatives of paeoniflorin; PcTx1, Pslogotoxin-1; HQH, Huai Qi Huang; BHGZD, Baihu-Guizhi decoction; JWJG capsule, Jinwujiangu capsule.